

## Leaps by Bayer, Khloris to develop breakthrough anti-cancer vaccines

03 April 2019 | News

**Seed investment of Leaps by Bayer paves an exclusive leadership position for next generation oncology business**



Leaps by Bayer, the investment arm of the global life sciences company Bayer, and Khloris Biosciences, a biotechnology company, have announced that they have joined forces to develop novel, first-in-class anti-cancer vaccines based on human induced pluripotent stem cells (iPSCs).

This technology has the potential to address one of today's biggest issues in human health: to prevent and cure cancer.

Human iPSCs have potential as anti-cancer vaccines because they share the same characteristics of cancer cells, such as expression of tumor antigens and the ability to self-renew. Injecting iPSCs that genetically match the recipient, but that are unable to replicate, can safely expose the immune system to a variety of cancer-specific targets.

"Bayer's development expertise, commercial reach and worldwide network of R&D sites, combined with our scientific knowledge and technology, will increase the chances to bring this potential breakthrough option to patients in need," commented Prof. Joseph C. Wu, a co-founder of Khloris.

"This alliance is in line with our passion for developing truly innovative and disruptive cancer therapies that have a major and lasting impact on disease. Leaps by Bayer offered a unique investment concept that allows big ideas to flourish," stated Dr. Lynne A. Bui, co-founder and CEO of Khloris.